CCL3 and rheumatoid arthritis: Overall, our results suggest that BM-MSCs have propensity to inhibit the expression of the analyzed cytokines/chemokines at mRNA level in HG (with no statistical significance); while in RA patients this inhibitory trend is only verified for IL-1β in classical (p < 0.05) and non-classical monocytes, and for CCL3 in non-classical monocytes (p > 0.05), as showed in Figure 6.